Capricor reports positive HOPE-3 trial results for Duchenne therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
March 12, 2026 9:01 AM EDTReduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022)Significant improvement in LVEF versus placebo in patients with baseline cardiomyopathy (p=0.017)Global Statistical Test (GST) composite endpoint showed significant overall treatment benefitDuchenne Video Assessment (DVA) showed approximately 83% slowing of disease progression (p=0.018), consistent with mid-level (elbow) PUL v2.0 resultsDeramiocel BLA currently under FDA review with a PDUFA target action date of August 22, 2026
SAN DIEGO, March... More
